Overview A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients Status: Completed Trial end date: 2016-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX. Phase: Phase 2 Details Lead Sponsor: Ionis Pharmaceuticals, Inc.